Recurrent Sarcoma: Clinical Trials

2 trials for Recurrent Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting. 2 Not applicable.

By phase and status

PhaseTrialsStatus
Not applicable2Completed 1, Recruiting 1

Follow Recurrent Sarcoma: new trials by email Literature Review of Recurrent Sarcoma trials Research Report on Recurrent Sarcoma

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice - Metastatic Sarcoma, Recurrent Sarcoma
Not applicableRecruitingM.D. Anderson Cancer Center202025-02-252026-08-11
Radiotherapy With Hyperthermia in Recurrent and Radiation-Induced Sarcomas
Hypofractionated radiotherapy, Hyperthermia, Hypofractionated radiotherapy with boost - Radiation Induced Neoplasms, Radiation-Induced Cancer
Not applicableCompletedMaria Sklodowska-Curie National Research Institute of Oncology202019-10-232025-04-30

Narrower conditions

Sarcoma (2)  ·  Neoplasms, Radiation-Induced (1)

Broader conditions

Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Connective and Soft Tissue (2)  ·  Radiation Injuries (1)  ·  Wounds and Injuries (1)

Interventions

Diathermy (1)  ·  Doxorubicin (1)  ·  Everolimus (1)  ·  Ifosfamide (1)  ·  Irinotecan (1)  ·  Polyethylene Glycols (1)  ·  Radiation Dose Hypofractionation (1)  ·  Sirolimus (1)  ·  Temozolomide (1)  ·  Vincristine (1)  ·  ganitumab (1)  ·  pazopanib (1)  ·  polyethylene glycol 400 (1)  ·  polyethylene glycol 8000 (1)  ·  temsirolimus (1)

Sponsors

M.D. Anderson Cancer Center (1)  ·  Maria Sklodowska-Curie National Research Institute of Oncology (1)

Countries

Poland (1)  ·  United States (1)

Top investigators

Joseph Ludwig, MD (1)

NIH funding

R01CA180279 (1)